Lennart Minthon (Former)
81 – 90 of 304
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2014
-
Mark
Low Levels of Soluble NG2 in Cerebrospinal Fluid from Patients with Dementia with Lewy Bodies.
(2014) In Journal of Alzheimer's Disease
- Contribution to journal › Article
-
Mark
Increased Levels of Hyaluronic Acid in Cerebrospinal Fluid in Patients with Vascular Dementia.
- Contribution to journal › Article
-
Mark
Factors that affect life-span in mild versus moderate Alzheimer’s disease.
(2014) 13th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy In Neurobiology of Aging 35(Suppl. 1). p.25-25
- Contribution to journal › Published meeting abstract
-
Mark
Early- versus Late-onset Alzheimer’s Disease—3-year Outcomes of Cholinesterase Inhibitor Treatment in Routine Clinical Practice.
(2014) 7th Clinical Trials Conference on Alzheimer’s Disease (CTAD)
- Contribution to conference › Poster
-
Mark
The effect of functional capacity and concomitant medications on life expectancy in Alzheimer’s disease.
(2014) Alzheimer’s Association International Conference (AAIC), 2014
- Contribution to conference › Poster
-
Mark
Prevalence of Lewy body dementia and neuroleptic treatment in nursing homes in Malmö, Sweden.
(2014) Alzheimer’s Association International Conference (AAIC), 2014
- Contribution to conference › Poster
-
Mark
White matter hyperintensities as a confounder in diffusion tensor imaging analysis of elderly cohorts
(2014) ISMRM-ESMRMB
- Contribution to conference › Abstract
-
Mark
Solitary living in Alzheimer's disease over 3 years: association between cognitive and functional impairment and community-based services.
- Contribution to journal › Article
-
Mark
Accuracy of Brain Amyloid Detection in Clinical Practice Using Cerebrospinal Fluid β-Amyloid 42: A Cross-Validation Study Against Amyloid Positron Emission Tomography.
- Contribution to journal › Article
- 2013
-
Mark
Mild versus Moderate Stage of Alzheimer’s Disease—Three-year Outcomes of Cholinesterase Inhibitor Therapy in a Routine Clinical Setting.
- Contribution to conference › Abstract
